STAT stories you may have missed

Wonder why biosimilars have been such a flop? STAT has all the answers in a comprehensive new report. 

The coronavirus outbreak could throw a serious wrench into the U.S. drug supply chain. 

How fast can biotech come up with a vaccine for coronavirus?

What does the controversial approval of a new muscular dystrophy drug mean for the FDA? STAT’s biotech braintrust discusses. 

Patient groups often get funded by pharma, but they rarely disclose that funding. 

Pharma is still not adequately tackling antimicrobial resistance. 

Meet ‘the gurus of sperm’: Ohana Biosciences is taking a different approach to fertility. 

STAT spoke with Gates Foundation CEO Sue Desmond-Hellmann about how she defines success, the future of drug R&D, and what’s next for her.